14 research outputs found
Galectin-3 and its relation with the risk of mortality and repeated readmissions due to cardiovascular causes.
<p>Gal-3 was modelled linearly with the gradient of risk, and centered at a threshold of risk of 17.8 ng/ml. A) Gal-3 and the risk of cardiovascular mortality in patients with CA125 >67 U/ml. B) Gal-3 and the risk of cardiovascular mortality in patients with CA125 â€67 U/ml. C) Gal-3 and the risk of cardiovascular rehospitalization in patients with CA125 >67 U/ml. D) Gal-3 and the risk of cardiovascular rehospitalization in patients with CA125 â€67 U/ml. Estimates for cardiovascular mortality adjusted for age, etiology, prior admission for acute heart failure, left ventricular ejection fraction<50%, glomerular filtration rate, NT-pro brain natriuretic peptide, treatment with beta blocker and treatment with angiotensin converting enzyme inhibitor. Estimates for cardiovascular rehospitalization adjusted for age, etiology, prior admission for acute heart failure, left ventricular ejection fraction, pleural effusion, prior stroke, prior myocardial infarction, implantable cardiac defibrillator, blood urea nitrogen, NT-pro brain natriuretic peptide, and treatment with beta blocker. Gal-3: galectin-3; CA125: antigen carbohydrate 125.</p
CA125/Gal-3 categories and risk of adverse events.
<p>CA125: carbohydrate antigen 125; Gal-3: galectin-3; HR; hazard ratio; IRR: incident rate ratio.</p><p>CA125/Gal-3 categories and risk of adverse events.</p
Galectin-3 and its relation with the risk of all-cause mortality expressed as adjusted hazard ratios.
<p>Gal-3 was modelled linearly with the gradient of risk, and centred at a threshold of risk of 17.8 ng/ml. A) Gal-3 and the risk of all-cause mortality in patients with CA125 >67 U/ml; B) Gal-3 and the risk of all-cause mortality in patients with CA125 â€67 U/ml. CA125: antigen carbohydrate 125; Gal-3: galectin-3.</p
Kaplan-Meier curve depicting the cumulative mortality rates across CA125 and galectin-3 categories.
<p>CA125: antigen carbohydrate 125.</p
Galectin-3 and its relation with the risk of all-cause rehospitalization expressed as incidence rate ratios.
<p>Gal-3 was modelled linearly with the gradient of risk, and centered at a threshold of risk of 17.8 ng/ml. A) Gal-3 and the risk of all-cause rehospitalization in patients with CA125 >67 U/ml. B) Gal-3 and the risk of all-cause rehospitalization in patients with CA125 â€67 U/ml. CA125: antigen carbohydrate 125; Gal-3: galectin-3. This differential prognostic effect was also observed when CV readmissions were evaluated as endpoint (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0122360#pone.0122360.g004" target="_blank">Fig 4B</a>).</p
Galectin-3 and its relation with the risk of mortality and repeated readmissions due to cardiovascular causes.
<p>Gal-3 was modelled linearly with the gradient of risk, and centered at a threshold of risk of 17.8 ng/ml. A) Gal-3 and the risk of cardiovascular mortality in patients with CA125 >67 U/ml. B) Gal-3 and the risk of cardiovascular mortality in patients with CA125 â€67 U/ml. C) Gal-3 and the risk of cardiovascular rehospitalization in patients with CA125 >67 U/ml. D) Gal-3 and the risk of cardiovascular rehospitalization in patients with CA125 â€67 U/ml. Estimates for cardiovascular mortality adjusted for age, etiology, prior admission for acute heart failure, left ventricular ejection fraction<50%, glomerular filtration rate, NT-pro brain natriuretic peptide, treatment with beta blocker and treatment with angiotensin converting enzyme inhibitor. Estimates for cardiovascular rehospitalization adjusted for age, etiology, prior admission for acute heart failure, left ventricular ejection fraction, pleural effusion, prior stroke, prior myocardial infarction, implantable cardiac defibrillator, blood urea nitrogen, NT-pro brain natriuretic peptide, and treatment with beta blocker. Gal-3: galectin-3; CA125: antigen carbohydrate 125.</p
Additional file 3: of Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients
Table S3. Cox regression analyses for 1-year HF-related hospitalization. A competing risk strategy using the Gray method was adopted, considering death as the competing risk in both univariate and multivariate Cox regression analyses. (DOCX 27Â kb
Additional file 1: of Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients
Table S1. Correlations between studied biomarkers. Correlation between the different studied biomarkers was performed using Pearson correlation test of log-transformed values of each biomarker. (DOCX 25Â kb
Additional file 2: of Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients
Table S2. Cox regression analyses for 30-day rehospitalization. A competing risk strategy using the Gray method was adopted, considering death as the competing risk in both univariate and multivariate Cox regression analyses. (DOCX 27Â kb
Kaplan-Meier survival curve according to EPC quartiles.
<p>Kaplan-Meier survival curve according to EPC quartiles.</p